Cargando…

Xanthonychia Due to Staining From Carbidopa-Levodopa

Detalles Bibliográficos
Autores principales:	Hwang, Jonathan Kyle, Lipner, Shari R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mattioli 1885 2023
Materias:	Image Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412056/ https://www.ncbi.nlm.nih.gov/pubmed/37557135 http://dx.doi.org/10.5826/dpc.1303a157

Ejemplares similares

Membranous nephropathy associated with the use of levodopa-carbidopa combination
por: Chaitanya, V., et al.
Publicado: (2015)

Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
por: Othman, Ahmed A., et al.
Publicado: (2017)

Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet(®)), sustained‐release carbidopa‐levodopa (Sinemet(®) CR), and carbidopa‐levodopa‐entacapone (Stalevo(®))
por: Hsu, Ann, et al.
Publicado: (2015)

Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication
por: Vijiaratnam, Nirosen, et al.
Publicado: (2017)

Effects of levodopa/carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy
por: Loens, Sebastian, et al.
Publicado: (2017)

Levodopa/carbidopa: Hallucinations: case report
Publicado: (2022)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
por: Müller, Thomas, et al.
Publicado: (2022)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
por: Nishikawa, Noriko, et al.
Publicado: (2022)

Coadministration With Carbidopa Enhances the Antimyopic Effects of Levodopa in Chickens
por: Thomson, Kate, et al.
Publicado: (2021)

Reply to letter: Suicide in Parkinson's disease patients treated with levodopa‐carbidopa Intestinal Gel
por: Fernandez, Hubert H., et al.
Publicado: (2015)

Population Pharmacodynamics of IPX066: An Oral Extended-Release Capsule Formulation of Carbidopa–Levodopa, and Immediate-Release Carbidopa–Levodopa in Patients With Advanced Parkinson’s Disease
por: Mao, Zhongping, et al.
Publicado: (2013)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
por: LeWitt, Peter, et al.
Publicado: (2023)

Improvement of Primary Writing Tremor in Parkinson’s Disease with Carbidopa/Levodopa
por: Battista, James P., et al.
Publicado: (2015)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
por: Margolesky, Jason, et al.
Publicado: (2017)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
por: Bigman, Daniel Y, et al.
Publicado: (2018)

Pharmacokinetics of Rytary(®), An Extended-Release Capsule Formulation of Carbidopa–Levodopa
por: Mittur, Aravind, et al.
Publicado: (2017)

Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation
por: Noui, Yassine, et al.
Publicado: (2021)

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
por: Park, Kye Won, et al.
Publicado: (2020)

Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective
por: Brooks, David J
Publicado: (2008)

Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety
por: Othman, Ahmed A., et al.
Publicado: (2015)

Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules
por: Modi, Nishit B., et al.
Publicado: (2019)

Integrated safety of levodopa‐carbidopa intestinal gel from prospective clinical trials
por: Lang, Anthony E., et al.
Publicado: (2015)

Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson’s Disease: Clinical Trial Post Hoc Analyses
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease
por: Poulopoulos, Markos, et al.
Publicado: (2010)

Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics
por: Standaert, David G., et al.
Publicado: (2018)

Proposition of zinc supplementation during levodopa–carbidopa intestinal gel treatment
por: Matsuyama, Hirofumi, et al.
Publicado: (2018)

Long‐term safety and effectiveness of levodopa‐carbidopa intestinal gel infusion
por: De Fabregues, Oriol, et al.
Publicado: (2017)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
por: Öthman, Mezin, et al.
Publicado: (2021)

Levodopa–carbidopa intrajejunal infusion in Parkinson’s disease: untangling the role of age
por: Morgante, Francesca, et al.
Publicado: (2020)

Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson’s disease patients with wearing-off
por: Kuoppamäki, Mikko, et al.
Publicado: (2015)

Eruptive melanocytic nevi in a patient with Parkinson disease treated by carbidopa-levodopa
por: Haraszti, Samantha, et al.
Publicado: (2018)

Levodopa-carbidopa intestinal gel therapy may cause “Supra-ON freezing of gate” in patients with Parkinson's disease with diphasic dyskinesia
por: Oshiro, Saki, et al.
Publicado: (2021)

Implementing Levodopa‐Carbidopa Intestinal Gel for Parkinson Disease: Insights from US Practitioners
por: Burack, Michelle, et al.
Publicado: (2018)

Concomitant Medication Usage with Levodopa‐Carbidopa Intestinal Gel: Results from the COSMOS Study
por: Fasano, Alfonso, et al.
Publicado: (2021)

Levodopa/carbidopa and entacapone in the treatment of Parkinson’s disease: efficacy, safety and patient preference
por: Müller, Thomas
Publicado: (2009)

Effect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
por: Antonini, Angelo, et al.
Publicado: (2016)

Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease
por: Hauser, Robert A, et al.
Publicado: (2018)

Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients
por: Senek, Marina, et al.
Publicado: (2018)

Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety
por: Poewe, Werner, et al.
Publicado: (2019)

Problems related to levodopa‐carbidopa intestinal gel treatment in advanced Parkinson's disease
por: Udd, Marianne, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vq85rle7qtuhhfm193b3hfsqkq